U.S. Offers New HTLV-1 Vaccine Technology for Licensing
Published Date: 7/2/2026
Notice
Summary
The National Cancer Institute has created a new vaccine to stop HTLV-1, a virus that can cause serious diseases like leukemia. Right now, no vaccine exists, so this invention could protect millions, especially in underserved areas. They’re looking for partners to help develop and license this promising vaccine, which could save lives and reduce healthcare costs in the near future.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Potential HTLV-1 Vaccine Could Cut Disease Burden
The invention is a preventive nucleic acid-based vaccine that produces HTLV-1 virus-like particles and is intended to protect against HTLV-1 infection, which is linked to adult T-cell leukemia/lymphoma (ATLL) and HAM/TSP. The notice states this vaccine could protect millions—particularly in underserved global regions—and reduce healthcare costs and the economic burden of treating related diseases; it is currently being tested in non-human primates.
Government Vaccine Licensing Opportunity
The National Cancer Institute is seeking research co-development partners and/or licensees for a nucleic acid-based chimeric virus-like particle (VLP) vaccine to prevent HTLV-1 infection (NIH Reference Number E-126-2022). The technology is at the preclinical (in vivo validation) stage and is available for licensing and commercial development.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20151, Notice of NIH Tribal Consultations and Listening Session
The NIH is inviting Tribal leaders and members to join two important meetings and a listening session during the National Congress of American Indians Annual Convention in October 2026. They’ll talk about new health research projects, renewing support for Tribal health centers, and shaping a new Tribal Data Sovereignty Policy. Tribes can also send their thoughts by November 20, 2026, helping shape future health programs and policies.
2026-19718, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding two closed virtual meetings in October 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists and research teams applying for grants should note these dates as they impact funding decisions but don’t involve public attendance.
2026-19804, Submission for OMB Review; 30-Day Comment Request; Generic Clearance for NIH Citizen Science and Crowdsourcing Projects (Office of the Director)
The NIH is asking for approval to keep collecting info from citizen science and crowdsourcing projects, making it easier to gather public input on health research. This affects anyone involved in these projects and invites comments by October 28, 2026. No new costs or big changes, just a smooth way to keep the data flowing for better science!
2026-19719, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review is shortening a key meeting from two days to just one day on October 13, 2026, keeping the same 9 a.m. to 6 p.m. hours. This change affects members of the Surgical Sciences and Bioengineering review group and means less time in the room but no public access. No money changes or delays are expected—just a quicker, tighter meeting!
2026-19706, Draft NIH Policy on Sharing Summary Level Study Results With Clinical Research Participants
The NIH wants to make it easier for people who join clinical studies to get simple summaries of the study results. This new policy aims to boost trust and teamwork between researchers and participants, helping science move faster and better. They’re asking for your thoughts by October 26, 2026, so get ready to share your ideas!
2026-19431, Government-Owned Inventions; Availability for Licensing
The government is offering a new invention for licensing that makes stem cell transplants safer and less harsh, especially for leukemia patients and older folks. This tech uses a special protein to prepare patients for transplants without the tough side effects of chemo and radiation. Companies can start licensing this preclinical innovation now to help bring better treatments to market faster.
Previous / Next Documents
Previous: 2026-13478, Agency Information Collection Activities: Request for Comments; Revision of Currently Approved Information Collection(s): U.S. Department of Transportation, Individual Complaint of Employment Discrimination Form
The U.S. Department of Transportation is updating its form for people to report job discrimination. This affects current and former DOT employees or job applicants who want to file a complaint. The form takes about an hour to fill out, and the DOT is asking for comments by August 2, 2026, before finalizing the update—no big cost changes expected.
Next: 2026-13480, Government Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapy
The National Cancer Institute has created a special viral peptide that could help prevent and treat a serious liver cancer called HCC. This new discovery might lead to a vaccine or therapy that boosts the immune system to fight cancer better. Researchers and companies interested in developing this treatment can now license the technology, opening doors for faster progress and potential health benefits worldwide.